Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- New Research on Pine Bark (Pycnogenol) and Childhood Asthma
Study published in the November/December issue of Journal of Asthma shows decrease in asthma symptoms, use of rescue inhalers in mild to moderate asthmatics.
- New Research on Pine Bark (Pycnogenol) and Childhood Asthma
Study published in the November/December issue of Journal of Asthma shows decrease in asthma symptoms, use of rescue inhalers in mild to moderate asthmatics.
- New Research on Pine Bark (Pycnogenol) and Childhood Asthma
Study published in the November/December issue of Journal of Asthma shows decrease in asthma symptoms, use of rescue inhalers in mild to moderate asthmatics.
- New Study on Cancer Preventive Activity of Tomato Carotenoids Published in Molecular Cancer Therapeutics
New research links reduced cancer risk with tomato phytonutrients.
- New Study on Cancer Preventive Activity of Tomato Carotenoids Published in Molecular Cancer Therapeutics
New research links reduced cancer risk with tomato phytonutrients.
- New Study on Cancer Preventive Activity of Tomato Carotenoids Published in Molecular Cancer Therapeutics
New research links reduced cancer risk with tomato phytonutrients.
- New Study on Cancer Preventive Activity of Tomato Carotenoids Published in Molecular Cancer Therapeutics
New research links reduced cancer risk with tomato phytonutrients.
- New Study on Cancer Preventive Activity of Tomato Carotenoids Published in Molecular Cancer Therapeutics
New research links reduced cancer risk with tomato phytonutrients.
- New Study on Cancer Preventive Activity of Tomato Carotenoids Published in Molecular Cancer Therapeutics
New research links reduced cancer risk with tomato phytonutrients.
- Herbal Extract Effective in Migraine Prevention
New study published in the December 28 issue of the journal Neurology, indicates that extract of the traditional herb butterbur (Petasites hybridus) can help prevent painful migraine headaches.
- Herbal Extract Effective in Migraine Prevention
New study published in the December 28 issue of the journal Neurology, indicates that extract of the traditional herb butterbur (Petasites hybridus) can help prevent painful migraine headaches.
- Herbal Extract Effective in Migraine Prevention
New study published in the December 28 issue of the journal Neurology, indicates that extract of the traditional herb butterbur (Petasites hybridus) can help prevent painful migraine headaches.
- Herbal Extract Effective in Migraine Prevention
New study published in the December 28 issue of the journal Neurology, indicates that extract of the traditional herb butterbur (Petasites hybridus) can help prevent painful migraine headaches.
- Herbal Extract Effective in Migraine Prevention
New study published in the December 28 issue of the journal Neurology, indicates that extract of the traditional herb butterbur (Petasites hybridus) can help prevent painful migraine headaches.
- Herbal Extract Effective in Migraine Prevention
New study published in the December 28 issue of the journal Neurology, indicates that extract of the traditional herb butterbur (Petasites hybridus) can help prevent painful migraine headaches.
- Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Companies announce results of 453 patient multi-center trial, the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
- Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Companies announce results of 453 patient multi-center trial, the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
- Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Companies announce results of 453 patient multi-center trial, the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
- Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Companies announce results of 453 patient multi-center trial, the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
- Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Companies announce results of 453 patient multi-center trial, the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
- Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Companies announce results of 453 patient multi-center trial, the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
- SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial
twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete.
- SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial
twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete.
- SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial
twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete.
- SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial
twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases
Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases.
- Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases
Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases.
- Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases
Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases.
- Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases
Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Vitamin D Injections May Significantly Improve Survival in Dialysis Patients
Study to be published in the April Journal of the American Society of Nephrology, shows that 76% of those dialysis patients receiving any form of activated vitamin D were still alive at the end of a two-year period, compared with 59% of those not receiving the therapy; researchers suggest more studies.
- Vitamin D Injections May Significantly Improve Survival in Dialysis Patients
Study to be published in the April Journal of the American Society of Nephrology, shows that 76% of those dialysis patients receiving any form of activated vitamin D were still alive at the end of a two-year period, compared with 59% of those not receiving the therapy; researchers suggest more studies.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Former American Diabetes Association President, Francine R. Kaufman, M.D. Leads Investigation at the Childrens Hospital Los Angeles
Los Angeles, CA., February 15, 2005 – Nutrition 21, Inc. (NASDAQ: NXXI) announced today that the Childrens Hospital Los Angeles will conduct the first double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes. Francine R. Kaufman, MD, director of the Hospital’s Comprehensive Childhood Diabetes Center, is the principal investigator in the seven-month study, to determine if adding 600 mcg of chromium as chromium picolinate to the daily diet of patients 12 to 18 years of age will improve blood glucose and body weight. It is estimated that one in 400 children, or 5 to 10% of the 13 million Americans diagnosed with diabetes, have type 1 diabetes, also known as juvenile diabetes.1
Thirty (30) study participants include female and male patients between the ages of 12 to 18 years with type 1 diabetes for more than one year with a glycosolated hemoglobin (HbA1c) of 7.0% or greater within the last three months and a body mass index (BMI) greater than the 85th percentile for age and gender. The primary outcome measure is HbA1c levels, which measures long-term glycemic control. Secondary outcome measures include blood glucose levels, body weight and BMI, along with cardiac risk factors including lipid profiles, enzymes and blood pressure.
More than 15 scientific studies support the safety and role of chromium in improving insulin function and glucose metabolism in people with type 2 diabetes and related conditions.2 “There is strong scientific evidence to suggest that supplemental chromium picolinate may improve insulin sensitivity, blood glucose control, and cardiovascular risk factors in adults with type 2 diabetes,” according to Dr. Kaufman, former president of the American Diabetes Association and specialist in pediatric endocrinology. “It is of great interest to us to see if chromium picolinate will help young people better manage their diabetes to maximize their long-term health and quality of life.”
Chromium is an essential trace mineral critical to proper insulin function and necessary for carbohydrate, fat and protein metabolism. “We are very pleased to work with Dr. Kaufman on determining chromium’s role in helping treat children with type 1 diabetes,” said James Komorowski, MS, vice president of technical services and scientific affairs, Nutrition 21, Inc., which supplied Chromax® chromium picolinate for the clinical trial. “Chromium picolinate is gaining acceptance among the medical community as a simple, affordable and well-tolerated adjunct nutritional therapy for people with diabetes. This study is important because of the growing need for a safe and effective method of treating insulin resistance in children with and at risk for diabetes.”
People with type 1 diabetes have twice the normal risk for death as people without diabetes and must take insulin in order for their bodies to metabolize sugar into energy.3 Peak incidence occurs around 10 to 12 years of age in girls and 12 to 14 years of age in boys. In addition, according to the American Diabetes Association, type 1 diabetes has shown to shorten the life span of an individual by 12 – 16 years.
About Nutrition 21, Inc.
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax® chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome®, which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.
Visit www.childrenshospitalla.org for more information on Childrens Hospital Los Angeles.
# # #
1National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2003. Rev. ed. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2004.
2Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27(11):2741-2751.
3Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2002. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2003.
Contact:
Stacey Antine, MS, RD,
914-701-4567
|